83664-33-9

Basic information

• Product Name: 2-BENZYLOXY-5-BROMOPYRIDINE
• Synonyms: 2-BENZYLOXY-5-BROMOPYRIDINE;5-BROMO-2-BENZYLOXYPYRIDINE;5-bromo-2-(phenylmethoxy)pyridine;6-Benzyloxy-3-bromopyridine
• CAS NO: 83664-33-9
• Molecular Formula: C₁₂H₁₀BrNO
• Molecular Weight: 264.1179
• Product Categories: blocks;Bromides;Pyridines
• Mol File: 83664-33-9.mol

Chemical Properties

• Melting Point: 45-48°C
• Boiling Point: 331.248 °C at 760 mmHg
• Flash Point: 154.133 °C
• Appearance: /
• Density: 1.439
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.605
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 1.56±0.22(Predicted)
• CAS DataBase Reference: 2-BENZYLOXY-5-BROMOPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BENZYLOXY-5-BROMOPYRIDINE(83664-33-9)
• EPA Substance Registry System: 2-BENZYLOXY-5-BROMOPYRIDINE(83664-33-9)

Safety Data

• Hazardous Substances Data: 83664-33-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-BENZYLOXY-5-BROMOPYRIDINE is used as a building block for the synthesis of pharmaceutical drugs and organic compounds. Its unique structure and functional groups make it a valuable component in the development of new medications and therapeutic agents.
Used in Chemical Industry:
2-BENZYLOXY-5-BROMOPYRIDINE is used as a reagent in various chemical reactions, facilitating the formation of desired products and improving the efficiency of chemical processes.
Used in Analytical Chemistry:
2-BENZYLOXY-5-BROMOPYRIDINE is used as a reference standard in analytical chemistry, providing a reliable benchmark for the calibration and validation of analytical methods and instruments.
Used in Research and Development:
2-BENZYLOXY-5-BROMOPYRIDINE is utilized in research and development efforts to explore its potential biological and pharmacological properties. Its unique structure and functional groups make it a promising candidate for the discovery of new active pharmaceutical ingredients and the advancement of drug development.

InChI:InChI=1/C12H10BrNO/c13-11-6-7-12(14-8-11)15-9-10-4-2-1-3-5-10/h1-8H,9H2

Upstream product

• 624-28-2 2,5-dibromopyridine 
• 100-51-6 benzyl alcohol 
• 53939-30-3 5-bromo-2-chloropyridine 
• 13472-85-0 2-methoxy-5-bromopyridine 
• 13466-38-1 5-bromopyridin-2(1H)-one 
• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 
• 766-11-0 5-bromo-2-fluoropyridine 
• 39856-50-3 5-bromo2-nitropyridine 
• 13466-38-1 5-bromopyridin-2-ol 

Downstream Products

• 106154-28-3 6-Benzyloxy-4'H-[3,4']bipyridinyl-1'-carboxylic acid ethyl ester 
• 861884-65-3 4-(6-benzyloxy-pyridin-3-yl)-morpholine 
• 40864-08-2 2-benzyloxypyridine 
• 861884-69-7 1-(6-benzyloxy-pyridin-3-yl)-4-methyl-piperazine 
• 861884-75-5 (6-benzyloxy-pyridin-3-yl)-hexyl-amine 
• 861884-68-6 8-(6-benzyloxy-pyridin-3-yl)-1,4-dioxa-8-aza-spiro[4.5]decane 
• 861884-72-2 (6-benzyloxy-pyridin-3-yl)-m-tolyl-amine 
• 861884-71-1 (6-benzyloxy-pyridin-3-yl)-methyl-phenyl-amine 
• 861884-73-3 (6-benzyloxy-pyridin-3-yl)-(4-fluoro-phenyl)-amine 
• 861884-70-0 tert-butyl 4-(6-(benzyloxy)pyridin-3-yl)piperazine-1-carboxylate 
• 635712-99-1 6-benzyloxypyridine-3-carboxaldehyde 
• 1046143-60-5 5-benzyl-2-(benzyloxy)pyridine 
• 518354-98-8 2-(benzyloxy)-5-(1,1,1-tributylstanyl)pyridine 
• 1265919-07-0 6-(benzyloxy)-3,3'-bipyridine 

Relevant articles and documents

PIPERIDIN-1- YL-N-PYRYDI NE-3-YL-2-OXOACET AM IDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MT A-ACCUMULATING CANCERS

Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R6, R7, R8 and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

Optimization of Triarylpyridinone Inhibitors of the Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral Potency

Non-covalent inhibitors of the main protease (Mpro) of SARS-CoV-2 having a pyridinone core were previously reported with IC50 values as low as 0.018 μM for inhibition of enzymatic activity and EC50 values as low as 0.8 μM for inhibition of viral replication in Vero E6 cells. The series has now been further advanced by consideration of placement of substituted five-membered-ring heterocycles in the S4 pocket of Mpro and N-methylation of a uracil ring. Free energy perturbation calculations provided guidance on the choice of the heterocycles, and protein crystallography confirmed the desired S4 placement. Here we report inhibitors with EC50 values as low as 0.080 μM, while remdesivir yields values of 0.5-2 μM in side-by-side testing with infectious SARS-CoV-2. A key factor in the improvement is enhanced cell permeability, as reflected in PAMPA measurements. Compounds 19 and 21 are particularly promising as potential therapies for COVID-19, featuring IC50 values of 0.044-0.061 μM, EC50 values of ca. 0.1 μM, good aqueous solubility, and no cytotoxicity.

SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE

The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.

PYRIDONE DERIVATIVE COMPRISING HETEROATOMIC RING BUTANE SUBSTITUENT, FOR TREATING FIBROSIS AND INFLAMMATORY DISEASES

Disclosed is a compound for treating fibrosis-related diseases, and specifically disclosed are the compound represented by formula (I) and a pharmaceutically acceptable salt thereof.

ION CHANNEL MODULATORS

The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.

Zinc (II)-mediated selective O-benzylation of 2-Oxo-1,2-dihydropyridines systems

The selective O-benzylation of 2-oxo-1,2-dihydropyridines plays a critical role in organic synthesis of natural products and biological active molecules. Herein we report a novel ternary system of ZnO, ZnCl2 and N,N-diisopropylethylamine (DIEA), that is highly effective for selective O-benzylation of 2-oxo-1,2-dihydropyridines using abundant substituted benzyl halides and related substituted 2-oxo-1,2-dihydropyridines compounds. This process allows access to a variety of O-benzyl products under mild reaction conditions, which are important synthetic intermediates in the protection of functional groups, and represents a new method toward the development for the O-benzylation of 2-oxo-1,2-dihydropyridines.

Imidazopyrazine compound, and preparation method and application thereof

The invention belongs to the technical field of medicines and relates to an imidazopyrazine compound, and a preparation method and an application thereof. Specifically, the invention relates to a compound with a structure shown in a formula (I) defined in the specification, a pharmaceutically acceptable salt of the compound, a stereisomer of the compound or a prodrug of the compound, and an application of the compound, the pharmaceutically acceptable salt of the compound, the stereisomer of the compound or the prodrug of the compound to the preparation of drugs. The drugs are used for preventing and/or treating diseases and/or symptoms, related to the over-activity of Bruton's tyrosine kinases, of subjects. The invention furthermore relates to an application of the compound, pharmaceutically acceptable salts of the compound, the stereisomer of the compound or the prodrug of the compound to the preparation of preparations. The preparations are used for reducing or inhibiting the activity of the Bruton's tyrosine kinases in cells.

Mild and Regioselective N-Alkylation of 2-Pyridones in Water

A mild and regioselective N-alkylation reaction of 2-pyridones in water has been developed. Tween 20 (2% w/w) was added to create a micellar system for improved solubility of starting materials, which leads to enhanced reaction rates. The protocol demonstrated a wide substrate scope with good isolated yields (40-94%) for all of the 24 examples evaluated. High regioselectivity favoring N-alkylation over O-alkylation was observed for benzyl halides (>5:1), primary alkyl halides (>6:1), and bulky and less reactive secondary alkyl halides (>2.4:1).

CARBAMATE/UREA DERIVATIVES

The invention relates to compound of the formula (I) or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.

Carbamate/urea derivatives

The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.